Hydroxide Polymaltose Research Articles

Pica sebagai Manifestasi Anemia Defisiensi Besi: Suatu Laporan Kasus

Prevalence of anemia in Indonesia based on Basic Health Research (2018) was 23.7%. Symptoms of iron deficiency anemia were pallor, malaise, palpitation, shortness of breath, headache, sore tongue. But sometimes can be found abnormal behavior in the form of PICA. This article reports on a-52-year-old man who sought medical treatment and was diagnosed with iron deficiency anemia with pica manifestation. The pica manifestation was characterized by a repeated desire to consume raw rice due to bleeding from hemorrhoids. Patient was given oral iron replacement therapy contain 100 mg of Fe (III) hydroxide polymaltose complex and folic acid 0.35 mg alternating with vitamin C 500 mg daily. Total iron daily dose given were 200 mg, divided in two doses. The patient received dietary education and was advised to consult a Gastroenterohepatology Subspecialist for the management of hemorrhoids, but it has not been done yet. The desire for raw rice consumption disappeared and the hemoglobin level increased to 12.4 g/dL after six weeks of therapy. The patient continued to take iron supplements until January 2023 but did not have follow-up visits to the clinic. In January 2023, the patient underwent hemorrhoid surgery due to bleeding accompanied by and a non-reducible lump that had been present for three days. Iron supplements continued for one month post-operation and then discontinued. The latest hemoglobin level was 15.3 g/dL without iron supplements. The symptoms of pica in this patient disappeared along with an increased hemoglobin level, and the management of severe anemia in this patient showed an adequate response. Bleeding has never occurred again after the surgery. Curative measures for hemorrhoidal bleeding are crucial, while iron supplementation is only a supportive therapy.

Features of the course of stable exertional angina against the background of iron deficiency anemia in outpatient practice

Introduction. Iron-deficiency accompanies many diseases, including cardiovascular pathology, so timely diagnosis and correction of this condition is necessary. Aim. To study the features of the course of stable exertional angina against the background of iron deficiency anemia before and after correction with iron (III) polymaltose hydroxide in patients in primary health care using a computerized patient register. Materials and methods. 1210 patients with stable exertional angina aged 50–85 years (309 men, 901 women) were included. A special computer program was created for data analysis. In 500 out of 1210 patients, IDA was detected (385 women, 115 men). Mild anemia – 410 patients, moderate – 75, severe – 15. The main group – patients with stable exertional angina and Irondeficiency anemia (the first subgroup – patients treated with iron (III) polymaltose hydroxide and the second subgroup – patients who did not receive the drug iron (III) polymaltose hydroxide due to refusal of treatment or contraindications) and the control group – patients with stable exertional angina without Iron-deficiency anemia. All patients received standard therapy recommended for the treatment of stable exertional angina (the main group additionally received iron (III) polymaltose hydroxide). Results. In the first subgroup of the main group, after treatment with iron (III) hydroxide polymaltose, there was a statistically significant increase in hemoglobin levels by 11,7%, hematocrit by 5%, erythrocytes by 4%, serum iron by 112,8%, and an improvement in exercise tolerance by 48,7%, episodes of ST segment depression by 30,2%. In the second subgroup and the control group, there were no significant changes in the above parameters. Conclusion. Iron-deficiency anemia contributes to the severe course of stable exertional angina, which is confirmed by the high frequency of III-IV functional class exertional angina, a decrease in tolerance to exercise stress. Correction of Iron-deficiency anemia reduces the frequency of episodes of transient myocardial ischemia in the main group.

Results of Randomized Comparative Efficacy Study of Iron Deficiency Anemia Management in Children with Iron III Hydroxide Polymaltose Complex and Iron Sulfate

Background. The guidelines on selection between iron preparations, iron sulfate (IS) and iron III hydroxide polymaltose complex (HPC), for iron deficiency anemia (IDA) management in pediatrics are contradictory. Objective. The aim of the study is to compare efficacy and safety of iron (III) HPC and IS for IDA treatment in children. Materials and methods. Randomization of children (aged from 1 month to 18 years) with IDA into 2 therapeutic groups was implemented in 2019-2020. on pediatric districts of children’s city outpatient's clinic: IS dosage of 3 mg/kg/day and iron (III) HPC dosage of 5 mg/kg/day. Hemogram monitoring was performed every 14 days. The efficacy was compared according to the rate of Hb level increase, erythrocytes indices, and serum ferritin (SF) level at the recorded moment of Hb normalization. For the safety — the rate of adverse effects. Results. 65 children with IDA were included in the study and randomized into 2 groups, the median age was 2.3 years (1st; 3rd quartile = 1.1; 4.3). Hb level increase was comparable in both groups (0.34 (0.23; 0.48) g/L/day and 0.24 (0.21; 0.30) g/L/day, р = 0.891). IS is more effective than iron (III) HPC in terms of average red blood cell volume by the time of Hb normalization (83.5 (80.0; 86.7) fl against 80.7 (79.0; 82.0) fl, р = 0.006), and mean cellular hemoglobin content (28.9 (SD = 2.0) pg against 27.4 (SD = 1.8) pg, р = 0.004). The timing of SF levels normalization did not differ. Adverse effects to iron III HPC treatment occurred 5.5 times more frequently than to IS (p = 0.0001). Conclusion. The efficacy of IS and iron III HPC at standard doses is comparable. The advantage in tolerability and recovery of erythrocytic indices justifies the feasibility of using IS preparations in the first line of treatment for children with IDA.

Iron Supplementation in Anemic Pregnant Women: A Comparison of Different Prescription Options in Pakistan

Background & objectives: Many pregnant women in Pakistan have iron deficiency anemia (IDA), a dietary deficit. It affects both the mother's and the foetal' health. Oral iron supplementation usually relieves IDA symptoms. Oral iron supplements are hazardous to the GI mucosa, and sensitivity is common. Poor therapeutic compliance leads to treatment failure. Ferrous ascorbate (FeA) and iron hydroxide polymaltose complex (IPC) reportedly improve gastrointestinal discomfort and increase patient compliance compared to ferrous sulphate (FS). These preparations reportedly improve hemoglobin levels and iron stores more quickly than FS. This analysis compared FS's efficacy and safety to IPC and FeA. Place of Study: Rashid Latif Medical College Lahore Duration of Study: February 2019 and October 2021 Methods: It was a randomized, parallel, open label, investigation among pregnant women of gestational age from 10 to 28 weeks with moderate anemia. Patients were randomly selected to receive either FS, IPC or FeA. They were then followed up for 3 months to look for improvement in the hemoglobin levels and other hematological indicators or any adverse drug response. Results: With the exception of 3 months, when the FeA group had a significantly higher hemoglobin level in comparison to the FS group (P <0.05), the hemoglobin levels were comparable across the three groups. The overall risk profiles for side effects were likewise equal across the research groups, with the exception of epigastric discomfort, which was more frequently reported in the FS group. Conclusions: The findings of the study indicated that FS, IPC, and FeA all have an efficacy and safety profile in the treatment of IDA associated with pregnancy that is comparable to one another. Keywords Anemia, ferrous ascorbate , ferrous sulphate ,iron hydroxide polymaltose ,pregnancy

Dietary and nutritional interventions in children with cerebral palsy: A systematic literature review.

Cerebral palsy is an extremely severe brain injury associated with multiple nutritional and clinical issues, such as underweight, gastroesophageal reflux, constipation, and nutrient deficiency. Evidence-based dietary and nutritional interventions may improve the quality of life of children with cerebral palsy. Systematically review randomized clinical trials evaluating nutritional and dietary interventions in the clinical, nutritional, and neurodevelopmental aspects of children with cerebral palsy. A search was performed in electronic databases (LILACS, Medline, Web of Science, Embase, Scopus, Cochrane Library, ClinicalTrials.gov, Brazilian Digital Library of Theses and Dissertations, ProQuest Dissertations and Theses Database, OpenGrey) using keywords. The search was firstly performed in May 2020 and updated on June 18th, 2021. Eligible studies were randomized clinical trials, that included children between 2 and 12 years old, and evaluated the effect of nutritional or dietetic interventions on clinical, nutritional or neurodevelopmental outcomes. Risk of bias was investigated using the RoB-2 tool. The study was registered on PROSPERO (CRD42020181284). Fifteen studies were selected. Positive results included the use of whey-based or pectin-enriched enteral formulas for gastroesophageal reflux (n = 6); 25-hydroxy-vitamin D supplementation for hypovitaminosis D (n = 2); supplementation with lipid mixture or diet with high-density energy for improvements in anthropometric measures (n = 2); supplementation with probiotics, prebiotics, symbiotics or magnesium for constipation (n = 2); nutritional support system for gross motor function (n = 1); lactoferrin and iron hydroxide polymaltose for iron deficiency anemia (n = 1); and educational intervention to improve feeding skills (n = 1). The overall risk of bias was high for 60% of the studies, and some concerns were raised for the remaining 40%. Some promising dietary and nutritional interventions may promote important clinical improvements for patients with cerebral palsy. However, evidence is weak, as few clinical trials have been published with many methodological errors, leading to a high risk of bias.

EFFECT OF IRON (III)-HYDROXIDE POLYMALTOSE COMPLEX ON ANEMIA: A LITERATURE STUDY

Health is an important thing to be maintained in life. In the development of this era, many people, especially teenagers, do not pay attention to the intake of nutrients, iron, and protein that enter the body causing disease. One of the diseases that can be caused is anemia. According to the National Institute of Health (NIH) the cause of anemia can be caused by a lack of iron, vitamins, or chronic disease. In Indonesia, the occurence of anemia is fairly high. still quite high. To overcome anemia, iron complex compounds can be used because one of the things that causes anemia is a lack of iron in the body. This study aims to describe the application of iron (III)-hydroxide polymaltose complex as an effective compound in overcoming of iron deficiency anemia.This study was compiled from the online literature of local and international journals using secondary data that had been screened based on keywords. The results of the study concluded that iron (III)-Hydroxide Polymaltose Complex Compounds can be used to treat anemia.This literature study covers recently published (year > 2000) reports on iron (III)-Hydroxide Polymaltose Complex Compounds in overcoming the health problem of anemia.

Greener approach for process intensification of iron haematinics by membrane nanofiltration

Iron haematinics are high-volume, low-cost drug products used to treat anaemia. For the preparation of iron haematinics, the manufacturers depend heavily on multipurpose-batch or semi-batch reactors. Here, process intensification of haematinics was carried out using membrane nanofiltration as a major operation. A total of three haematinics namely, iron (III) hydroxide polymaltose, iron gluconate, and iron sucrose complex were prepared, and the process intensified on dead-end filtration set up by using a polymeric membrane. Iron (III) hydroxide polymaltose experimental results were compared with commercially available standard. The membrane performance was characterized by various parameters such as flux, permeability, flux decline ratio, flux recovery ratio, percentage retention, fouling, etc., at different transmembrane pressures. The membrane surface was analysed by Scanning Electron Microscopy (SEM) to understand its morphology and fouling. The iron concentration was detected in the permeate stream using inductively coupled plasma optical emission (ICP-OES) spectroscopy to detect %retention (>99.99%) under all experimental conditions tested. The study led to optimized conditions for haematinics concentration by a membrane at a 10-bar trans-membrane pressure, which was applied for the preparation of iron gluconate salt. Overall, the study resulted in a green process with increased productivity.

Use of oral iron in managing iron deficiency anemia in children with intestinal failure

Background & ObjectivesAs intestinal failure (IF) inhibits the digestive system from absorbing nutrients, total parenteral nutrition (TPN) is required to provide all of a person's nutritional demands. In children with malabsorptive conditions like IF, iron deficiency anemia (IDA) is common. This study used a quasi-experimental approach to assess the efficacy and safety of oral iron therapy in treating IDA in TPN-dependent children with IF. Materials and MethodsSixteen pediatric patients with an ongoing history of IF, TPN dependency, and iron deficiency anemia were enrolled and given an oral iron syrup dose of ferric hydroxide polymaltose complex (6 mg/kg/day in 2–3 separate doses of elemental iron) after receiving ethical approval and parental consent. Blood tests were done to measure serum iron, ferritin, complete iron-binding capacity [TIBC], transferrin saturation [TSAT], and hemoglobin (Hb) level at the time of inclusion (T0), 14 (T14), and 30 days after treatment (T30). ResultsThe mean age was 7.13 (±1.99) and female were 12 (75%). No remarkable change in Hb level was noted in the first and second subsequent follow-ups, notwithstanding, the normal estimation of the serum ferritin level significantly increased during the first follow-up (on fourteenth day) which further enhanced by second follow-up (30th day). The aggregate of the total iron binding capacity (TIBC) declined during the course of oral iron therapy with a reduction in transferrin saturation. Interpretation & ConclusionThe data suggest that oral iron therapy is unsuccessful in the treatment of IDA in children with IF. There is no substantial improvement in hemoglobin level or iron profile aside from serum ferritin. In order to avoid using parenteral iron in IF patients, an additional supportive system is needed to aid in the integration of oral iron therapy.

Protective effect of Beta vulgaris roots supplementation on anemic phenylhydrazine-intoxicated rats.

Anemia is a public health problem that affects many people worldwide. Beetroot (Beta vulgaris) is a plant supposed to have many healthy features. The present study was done to evaluate the anti-anemic effect of beetroot supplement on anemia induced by phenylhydrazine in albino rats. Fifty rats were randomly divided into five equal groups. The control group was kept normal rats. In the second group, anemia was induced in rats by intraperitoneal injection of phenylhydrazine at 60 mg/kg in 3 divided doses daily, for 3 consecutive days. The last three groups received phenylhydrazine as the anemic group. Then, the third group received beetroot extract in dose 200 mg/kg for 24 days. The fourth group received beetroot powder in dose 1000 mg/kg for 24 days. The last group received iron (III) hydroxide polymaltose complex in dose 5mg/kg for 24 days. Our results showed that hemolytic anemia induced by phenylhydrazine in rats caused alteration in the blood picture, iron indices, serum biochemical parameters, antioxidant biomarkers, and histopathological picture. However, the supplementation with beetroot ameliorated these alterations, especially beetroot powder which showed powerful health effects compared to beetroot extract and iron preparation.

Lactoferrin versus iron hydroxide polymaltose complex for the treatment of iron deficiency anemia in children with cerebral palsy: a randomized controlled trial.

Iron deficiency anemia (IDA) is common among children with cerebral palsy (CP), and studies on the efficacy of lactoferrin (Lf) in the treatment of IDA are limited. This study aimed to compare the efficacy of Lf with that of iron hydroxide polymaltose complex (IPC) in the treatment of IDA in children with CP. This randomized controlled study, conducted at Alexandria University Children's Hospital, enrolled 70 children aged 1-10 years with CP and IDA; 35 children randomly received IPC, whereas the other 35 received Lf. Four children withdrew from the study; thus, only 66 children were analyzed (32 in the IPC group and 34 in the Lf group). At baseline, the hemoglobin level and other blood parameters were similar between the two intervention groups. After four weeks of treatment, both the IPC and Lf groups showed significant improvements in hemoglobin (Hb), serum ferritin (SF), serum iron, total iron-binding capacity, mean corpuscular volume, and mean corpuscular hemoglobin from baseline. Upon comparing the two treatment groups, adjusted mean Hb and SF changes in the Lf group were significantly higher than that of the IPC group (p =0.001and p= 0.033, respectively), and constipation was less likely to occur in the Lf group than the IPC group (p = 0.049 ).Conclusion: Lactoferrin is effective and superior to IPC as an oral iron replacement therapy in children with CP and IDA, as it has fewer side effects. What is Known: • Lactoferrin (LF) is a natural glycoprotein capable of treating iron deficiency anemia (IDA). • Studies on the efficacy of Lf in the treatment of IDA in children with cerebral palsy (CP) are limited. What is New? • This trial compared the efficacy of Lf and iron hydroxide polymaltose complex (IPC) as treatments of IDA in children with CP. • Lf is effective and even better than IPC as a treatment of IDA in children with CP, as it has fewer side effects.

Kompleks polimaltozy z wodorotlenkiem żelaza w leczeniu niedoboru żelaza i niedokrwistości z niedoboru żelaza w okresie ciąży

Introduction. Iron deficiency (ID), and iron deficiency anaemia (IDA) are consistently associated with reduced maternal cognitive function and increased depressive disorders. In addition, the preterm delivery, and intra-uterine growth restriction were reported as an adverse neonatal outcome for ID and IDA. This study designed to evaluate the efficacy of ferric hydroxide polymaltose (FPM) in treatment of ID, and IDA during pregnancy. Materials and methods . One hundred and twenty-two women with ID (ferritin < 15 μg/L), and moderate IDA (haemoglobin ≥ 7 and < 10 g/dL) during pregnancy were included in this study. Studied women treated with FPM tablets for ≥ 3 months. The pre-treatment ferritin, haemoglobin, red blood cells (RBCs)-mean corpuscular volume (MCV), and -mean corpuscular haemoglobin (MCH) were compared by post-treatment values. Results. The mean pre-treatment ferritin, and haemoglobin significantly increased from 12.4 ± 5.6 μg/L and 7.8 ± 3.3 g/dL; respectively to 116.5 ± 6.9 μg/L and 11.1 ± 2.8 g/dL; respectively, 3-months’ after FPM treatment (p = 0.02 and 0.0002; respectively). In addition, the mean pretreatment RBCs MCV, and MCH significantly increased from 73.5 ± 4.6 fL and 24.2 ± 7.7 pg; respectively to 94.0 ± 3.8 fL and 31.7 ± 6.3 pg; respectively 3-months’ after FPM treatment (p = 0.02 and 0.01; respectively). Conclusion. The FPM (Ferose ® ) is an effective therapeutic option for treatment of ID, and IDA during pregnancy with high safety profile, and low side effects. The superior tolerability of FPM is an important advantage because compliance to oral iron is the main obstacle toward effective treatment of ID, and IDA during pregnancy.

Interventions for treating iron deficiency anaemia in inflammatory bowel disease.

Interventions for treating iron deficiency anaemia in inflammatory bowel disease.

A comparative study for the efficacy of lactoferrin-100 versus lactoferrin-100 and ferrous gluconate versus ferric hydroxide on irondeficiency anemia.

Objective: To estimate the effect of therapeutic doses of Lactoferrin 100, Lactoferrin 100 and ferrous gluconate compound, and Ferric Hydroxide polymaltose on the outcome of Iron Deficiency Anemia (IDA) in pediatric age group. Methods: 150 children aged above 2 years suffering from IDA were recruited from the Outpatient Clinic of Alexandria University Children's Hospital. Children with confirmed IDA randomly allocated into three subgroups, (50 children each), Group A were treated by Lactoferrin 100, one packet for 2 times daily, Group B were treated by Lactoferrin 100 and ferrous gluconate compound, one packet for 2 times daily, Group C treated by Ferric hydroxide polymaltose 6 mg/kg/day 3 times daily, all for 3 months after diagnosis. Results: There was no significant difference in the baseline levels of Hemoglobin (Hb), serum ferritin, serum iron (Fe), and total iron binding capacity among the three groups. In each group, all the biochemical indices were significantly improved when compared with baseline levels after 1.5 and 3 months of treatment (p=0.0001), but not for the mean of Fe in group A (Lactoferrin 100). There was no significant difference throughout the 3 month of treatment (p=0.700). There was a significant difference among the three groups as regards levels of Hb, iron and ferritin at 1.5 and 3 months of treatment, being the highest in the Lactoferrin 100 and ferrous gluconate compound group(B) (p=0.0001) followed by Ferric hydroxide polymaltose group(C). Conclusion: Lactoferrin with iron may be considered as a more effective alternative treatment than traditional iron salt preparations for treatment of IDA.

Comparison of efficacy & safety of iron polymaltose complex & ferrous ascorbate with ferrous sulphate in pregnant women with iron-deficiency anaemia.

Background & objectives:Iron-deficiency anaemia (IDA) is a common nutritional deficiency among pregnant women in India. It has a significant impact on the health of the mother as well as that of the foetus. IDA generally responds well to treatment with oral iron supplementation. However, oral iron supplements are toxic to the gastrointestinal mucosa and intolerance is common, resulting in poor compliance and failure of treatment. The iron salts such as iron hydroxide polymaltose complex (IPC) and ferrous ascorbate (FeA) are claimed to have low gastrointestinal intolerance, therefore better patient compliance than the conventionally used ferrous sulphate (FS). These preparations also claim to increase haemoglobin level faster as well as improve the iron storage better than FS. This study was done to compare the efficacy and safety of FS with IPC and FeA.Methods:It was a randomized, parallel, open label, study among pregnant women of gestational age between 12 to 26 wk with moderate anaemia. Patients were randomly allocated to receive either FS, IPC or FeA. They were then followed up for 90 days to observe for improvement in the haemoglobin levels and other haematological parameters or any adverse drug reaction.Results:The haemoglobin levels were comparable in the three groups except at day 90 when FeA group had significantly higher haemoglobin level as compared to FS group (P<0.05). The overall adverse effect profiles were also comparable among the study groups except epigastric pain which was more commonly reported in the FS group.Interpretation & conclusions:The results of the study showed that FS, IPC and FeA have comparable efficacy and safety profile in the treatment of IDA of pregnancy.

Частота и причины железодефицита у малочисленных народов Севера (ханты и манси), мигрировавших в город и ведущих традиционный образ жизни (стойбища, село), опыт применения препаратов железа

Objective. To study the health status of women from among the small-numbered indigenous peoples of the North (SIPN), including those leading a traditional way of life in camps and rural areas. Patients and methods. Using continuous sampling method, a prospective analysis of complaints, anamnestic, anthropometric, and laboratory data was carried out in female patients from among SIPN (Khanty and Mansi) living in rural areas and camps, as well as in the city of Khanty-Mansiysk. The comparison group consisted of women from the migrant population (Russians) living in the city of Khanty-Mansiysk. Results. The greatest number of health disorders was found among SIPN who migrated to the city in the first and second generations. Overweight was observed in 46.2% of women in this cohort, obesity was diagnosed in 19.2% of women. Heavy and prolonged menstrual bleeding was the main cause of iron deficiency (11.5%) and iron deficiency anemia (IDA) (30.8%) in the group of SIPN living in the city. IDA of mild severity occurred in 19.2% of patients, and of moderate severity – in 11.5%. Conclusion. Iron metabolism disorders were observed in 42.3% of women from among SIPN who migrated to the city. Iron(III)- hydroxide polymaltose complex (Ferrum Lek®), which is used in the complex therapy of gynecological diseases (menstrual disorders) and gastrointestinal diseases, has high efficiency, good tolerability and the least number of adverse effects. This makes it possible to recommend it for the treatment of IDA and for the replenishment of iron stores in women in both SIPN and newcomer populations. Key words: anemia, iron deficiency, female residents of the Khanty-Mansi Autonomous Area-Yugra, small-numbered indigenous peoples of the North (Khanty and Mansi), Ferrum Lek

Investigation on Haematinic accessible Assortments and Measurable Structures available in Indian Markets

To investigate Haematinic definitions accessible in India arcade for their assortments of measurements structures, hard salts utilized, the substance of essential iron, recurrence of organization compulsory, the occurrence of extra supplements, levelheadedness and price. Haematinic details recorded in IDR 2018, were investigated for salts of Iron present. Arrangements of ferrous fumarate were additionally investigated for Iron substance, presence of folic corrosive and other included extra parts. A sum of 522 plans, 291 (55.74%) was oral strong measurement structure, 206 (39.46%) were oral fluids and 25 (4.7%) were parenteral. Iron salts in these details were in a type of ferrous fumarate, carbonyl iron, iron ascorbate, iron ammonium citrate, ferric hydroxide polymaltose perplexing, ferrous sulfate, sodium hydrate. Carbonyl iron was available in 92 arrangements and was most ordinarily utilized readiness in oral strong plans. A few details moreover contained Vitamin B12, zinc sulfate, histidine, lysine different multivitamins and calcium arrangements in factor extent. Out of 291 oral strong, 45 (15.46 %) arrangements required organization &gt; three times each day to accomplish the remedial fixation. The normal expense of the sound planning was more than the normal expense of silly arrangement. Investigation of different haematinics shows there is no consistency in details. Iron and folic corrosive are included wide factor range in addition, different substances were additionally included with no very much demonstrated proof. Steps ought to be taken to normalize these details.

Анемизирующий синдром у современных женщин — нерешенная мировая проблема. Врачебная тактика

Objective of the Review: To set forth the frequency and prevalence of the anemia syndrome in non-pregnant and pregnant women and approaches to treating this disorder. Key Points: Anemia syndrome is the most common health problem in contemporary women. The leading cause of iron deficiency in women of reproductive age is abnormal uterine bleeding (AUB). Anemia in women significantly reduces their ability to work and quality of life, and increases the rates and severity of complications in pregnant women and parturients. It is also a significant contributor to maternal mortality and fetal and neonatal morbidity. Treating anemia in pregnant women presents certain challenges. In the period between the first trimester and delivery, there is an 8-fold increase in the requirement for iron; therefore, hemoglobin levels return to normal slowly. The active ingredient of Ferrum Lek is a ferric hydroxide polymaltose complex, which is as effective as medications containing ferrous sulfate, but is significantly better tolerated by patients and easier to use. The active transport of iron allows its controlled absorption from the polymaltose complex, minimizing the risk of an increase in serum levels of iron not bound to transferrin. This ensures that this medication is very safe and eliminates the risk of overdose or poisoning. Conclusion: Anemia syndrome is the most common type of homeostatic imbalance in women of reproductive age. It most often results from frequent and abundant uterine bleeding (AUB). Therefore, an obstetrician-gynecologist plays the leading role in identifying menstrual disorders and choosing therapies to reduce blood loss. A gynecologist will also work with an internist (hematologist) in treating iron deficiency anemia. Keywords: anemia syndrome, iron deficiency anemia, abnormal uterine bleeding, ferric hydroxide polymaltose complex.

Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure.

ObjectiveAnemia is common in patients with chronic heart failure (CHF). This study aimed to examine the frequency of iron deficiency anemia in patients with CHF. We investigated the effects of oral ferrous or ferric supplementation on prognosis of CHF and quality of life.MethodsA total of 201 patients with chronic decompensated heart failure were enrolled in a 6-month prospective study. Patients were randomly assigned to two groups. Patients in group I (n = 100) received ferrous fumarate and those in group II (n = 101) received ferric hydroxide polymaltose complex. Quality of life was measured by the 6-minute walking test (6MWT).ResultsA total of 49% of the patients had iron-dependent anemia in group I and 53.3% were anemic in group II. In group I, the number of anemic patients was significantly lower at 6 months after admission compared with at initial admission (49% versus 45%). Significant improvements were observed in hemoglobin values, the 6MWT distance, and New York Heart Association class after 6 months in both groups.ConclusionsIron deficiency is a significant comorbidity in CHF, even without anemia. Iron should be replaced orally or intravenously because it significantly improves the quality of life of patients.

Effect of treatment with single total-dose intravenous iron versus daily oral iron(III)-hydroxide polymaltose on moderate puerperal iron-deficiency anemia.

BackgroundIron-deficiency anemia is the most common nutritional cause of anemia in pregnancy and is often responsible for puerperal anemia. Puerperal anemia can impair postpartum maternal and neonatal well-being.ObjectiveTo determine the effect of treatment of moderate puerperal iron-deficiency anemia using a single intravenous total-dose iron dextran versus daily single dose oral iron(III)-hydroxide polymaltose.MethodologyA randomized controlled study in which postpartum women with moderate iron-deficiency anemia were randomized into treatment with either a single total-dose intravenous iron dextran or with daily single doses of oral iron(III)-hydroxide polymaltose tablets for 6 weeks. Effects on hemoglobin concentration using either method were compared at 6 weeks postpartum. Analysis was per protocol using SPSS version 17 for windows. P-values ≤0.05 were considered significant.ResultsTwo hundred eighty-four women were recruited for the study: 142 women received single total dose intravenous infusion of iron dextran while 142 received daily oral iron(III)-hydroxide polymaltose tablets. Approximately 84.0% (237/282) completed the study and were analyzed including 81% (115/142) of those randomized to injectable iron therapy compared to 85.9% (122/142) of those randomized to oral treatment. The proportions of women who had attained hemoglobin concentration of at least 10 g/dL by the 6 weeks postpartum visit did not differ significantly between cases and controls (95.7% vs 94.3%; P=0.73). Similarly, the mean increases in hemoglobin following either therapeutic route were comparable (1.03±0.56 g/dL for intravenous iron and 0.97±0.46 g/dL for the oral group; P=0.42).ConclusionSingle total-dose intravenous iron for treatment of puerperal iron-deficiency anemia was as effective as daily single doses of ferric iron tablets. For puerperal patients with iron-deficiency anemia in whom compliance with and tolerability of oral iron are not certain, a single total-dose intravenous iron can be safely offered.

ADMINISTRATION OF IRON(III)-HYDROXIDE POLYMALTOSE IN THE TREATMENT OF IRON DEFICIENCY ANEMIA IN CHILDREN

Purpose of the study. To study the clinical efficacy and safety of iron(III)-hydroxide polymaltose (Maltofer) in the treatment of iron deficiency anemia in children. Material and methods . A retrospective study of medical records of pediatic patients with iron deficiency anemia who received iron(III)-hydroxide polymaltose in standard doses during the course of inpatient treatment. Results. Administraton of iron(III)-hydroxide polymaltose was associated with a positive dynamics of the studied hematological parameters. No adverse reactions were reported. Girls demonstrated a more significant increase in hemoglobin levels and a more significant increase in the color index and mean cell hemoglobin compared to boys.